BMS claims first EU okay for adjuvant oesophageal cancer immunotherapyBristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy Share XBMS claims first EU okay for adjuvant oesophageal cancer immunotherapyhttps://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/
BMS pulls speedy Opdivo approval for liver cancer in USBristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for Share XBMS pulls speedy Opdivo approval for liver cancer in UShttps://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/
Look out BMS, Cytokinetics has its eye on mavacamten’s turfShares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) Share XLook out BMS, Cytokinetics has its eye on mavacamten’s turfhttps://pharmaphorum.com/news/look-out-bms-cytokinetics-has-its-eye-on-mavacamtens-turf/
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorDuring the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at Share XThe key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorhttps://pharmaphorum.com/partner-content/the-key-to-psoriasis-innovation-dispelling-the-shadow-of-the-jak-inhibitor/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyJust a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into Share XBMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyhttps://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/
EU okays BMS’ azacitidine pill for first-line maintenance of AMLBristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that Share XEU okays BMS’ azacitidine pill for first-line maintenance of AMLhttps://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/
BMS pays $650m upfront for Eisai’s first ADC candidate for cancerJapan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing Share XBMS pays $650m upfront for Eisai’s first ADC candidate for cancerhttps://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/
EHA21: Study raises BMS’ hopes for Reblozyl in less severe diseaseBristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after Share XEHA21: Study raises BMS’ hopes for Reblozyl in less severe diseasehttps://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/
